Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-IFN-SA in HCV
NCT01605513Phase 2Completed
- Sponsor
- The First Hospital of Jilin University
- Start
- Jun 2011
- Primary completion
- Dec 2013
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of peginterferon alfa-2a in hepatitis C (HCV) (7 arms), sponsored by The First Hospital of Jilin University. Primary endpoint: Proportion of patients with undetectable HCV RNA at 12 weeks. Started Jun 2011; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01605513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01605513.